Efficacy and safety of sotagliflozin adjuvant therapy for type 1 diabetes mellitus: A systematic review and meta-analysis
Open accessAbstract
Background: To systematically evaluate the efficacy and safety of sotagliflozin (SOTA) adjuvant therapy for type 1 diabetes mellitus (T1DM). Methods: Through April 2019, the Web of Science, PubMed, Cochrane Library, Embase, and China National Knowledge Infrastructure databases were electronically searched to identify randomized controlled trials exploring SOTA adjuvant therapy for T1DM. Strict screening and quality evaluations of the obtained literature were performed independently by 2 researchers. Outcome indexes were extracted, and a meta-analysis of the data was performed using Revman 5.3 software. Results: A total of 7 randomized controlled trials were included. The meta-analysis results showed that compared with the patients in the placebo group, the patients in the SOTA group had a lower hemoglobin A1c (mean difference [MD] = −0.28, 95% confidence interval [CI] [−0.34, −0.22], P < .01), lower total daily insulin use (MD = −8.89, 95% CI [−11.64, −6.13], P < .01), faster weight loss (MD = −3.03, 95% CI [−3.79, −2.26], P < .01), better fasting blood glucose and 2-hour postprandial blood glucose control (MD = −0.75, 95% CI [−1.04, −0.45], P < .01; MD = −2.42, 95% CI [−3.17, −1.67], P < .01), and a higher rate of well-controlled glucose levels (relative risk = 1.75, 95% CI [1.55, 1.99], P < .01), while no significant difference in the incidence of severe hypoglycemic events was found between the SOTA and placebo groups (risk difference [RD] = −0.01, 95% CI [−0.02, 0.00], P = .13). The incidence of diabetic ketoacidosis was higher in the SOTA group than in the placebo group (RD = 0.03, 95% CI [0.02, 0.04], P < .01). The incidence of genital mycotic infection was higher in the SOTA group than in the placebo group (RD = 0.06, 95% CI [0.05, 0.08], P < .01). No significant difference in the incidence of urinary tract infections was detected between the SOTA group and the placebo group (RD = 0.00, 95% CI [−0.01, 0.01], P = 0.97). Conclusions: SOTA is a potential drug for the treatment of T1DM and is effective for controlling blood sugar. The main adverse reactions to SOTA are genital mycotic infections and diabetic ketoacidosis. We must further assess the severity of diabetic ketoacidosis caused by SOTA.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The SGLT1/2 inhibitor sotagliflozin has been studied in clinical trials in people with type 1 diabetes, and results showed improvements in A1C and body weight; however, sotagliflozin use was associated with an eightfold increase in DKA compared with placebo.
“The SGLT1/2 inhibitor sotagliflozin has been studied in clinical trials in people with type 1 diabetes, and results showed improvements in A1C and body weight (80); however, sotagliflozin use was associated with an eightfold increase in DKA compared with placebo (81).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [80]
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Handelsman, Y., Henry, R. R., Bloomgarden, Z. T., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Ferrannini, E., Fonseca, V. A., Garber, A. J., Grunberger, G., et al. (2016) · Endocrine Practice · doi:10.4158/ep161292.ps · Cited by 358 · see citing works
Zhang, Z., Xu, X., & Ni, H. (2013) · Critical Care · doi:10.1186/cc11919 · Cited by 295 · see citing works
Buse, J. B., Garg, S. K., Rosenstock, J., Bailey, T. S., Banks, P., Bode, B. W., Danne, T., Kushner, J. A., Lane, W. S., Lapuerta, P., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0343 · Cited by 234 · see citing works
Flagged first, then by citations
Research works printed but not linked: 22
- [1]Johnson E Warren F Skolnik N Diabetes update: your guide to the latest ADA standards. J Fam Pract 2016; 65: 310– 8. 27275934
- [2]Chia Y Ching S Chew B May measurement Month 2017 blood pressure screening: findings from Malaysia—South-East Asia and Australasia. Eur Heart J Suppl 2019; 21: Supplement_D: D77– 9. 31043885 PMC6479503
- [3]Rashid A Devaraj N Oh no! Now i have diabetes. Rawal Med J 2018; 43: 776– 8.
- [4]Xiao Y Li T Jia Y Influence of type 1 diabetes mellitus on the ocular biometry of Chinese children. J Ophthalmol 2019; 2019: 7216490. 30895160 PMC6393916
- [5]Armstrong C ADA updates standards of medical care for patients with diabetes mellitus. Am Fam Physician 2017; 95: 40– 3. 28075100
- [6]Chiang JL Maahs DM Garvey KC Type 1 Diabetes in children and adolescents: a position statement by the American Diabetes Association. Diabetes Care 2018; 41: 2026– 44. 30093549 PMC6105320
- [7]Piperidou A Sarafidis P Boutou A The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. J Hypertens 2019; 37: 1334– 43. 31145707
- [8]Raj H Durgia H Palui R SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: a systematic review. World J Diabetes 2019; 10: 114– 32. 30788048 PMC6379733
- [9]Ader P Block M Pietzsch S Interaction of quercetin glucosides with the intestinal sodium/glucose co-transporter (SGLT-1). Cancer Lett 2001; 162: 175– 80. 11146223
- [10]Sands AT Zambrowicz BP Rosenstock J Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care 2015; 38: 1181– 8. 26049551 PMC4831906
- [11]Baker C Wason SPB A 12-week dose-ranging study of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes (inTandem4). Diabetologia 2017; 60: S409.
- [12]Bode B Banks P Strumph PSS Efficacy and safety of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct to insulin in young adults with poorly controlled type 1 diabetes. Diabetologia 2017; 60: S87– 8.
- [14]Danne T Cariou B Banks P HbA1c and hypoglycemia reductions at 24 and 52 Weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 study. Diabetes Care 2018; 41: 1981– 90. 29937431
- [15]Danne T Cariou B Buse JB Improved time in range and glycemic variability with sotagliflozin in combination with insulin in adults with type 1 diabetes: a pooled analysis of 24-week continuous glucose monitoring data from the inTandem program. Diabetes Care 2019; 42: 919– 30. 30833371 PMC6905498
- [16]Garg SK Henry RR Banks P Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med 2017; 377: 2337– 48. 28899222
- [17]Giaccari A Sodium-glucose co-transporter inhibitors: medications that mimic fasting for cardiovascular prevention. Diabetes Obes Metab 2019; 21: 2211– 8. 31209982
- [18]Baranowska A Stefanowicz-Rutkowska M Matuszewski W New antidiabetic drugs: current status and future prospects - a review of the literature. Wiad Lek 2018; 71: 1588– 98. 30684345
- [19]Dixit D Yoon Y Volino LR Empagliflozin: a sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes. Am J Health Syst Pharm 2015; 72: 1943– 54. 26541949
- [20]Markham A Keam SJ Sotagliflozin: first global approval. Drugs 2019; 79: 1023– 9. 31172412
- [21]Lamos EM Hedrington M Davis SN An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors. Expert Opin Drug Saf 2019; 18: 691– 701. 31150300
- [22]Bashir J Nalla P Peter R A case series of DKA occurring in patients receiving treatment with SGLT-2 inhibitors. Diabetes Obes Metab 2018; 20: 1800– 1. 29493069
- [23]Martinez E Portillo N Lizarralde E For debate: paediatric T1DM: DKA is still a problem. Pediatr Endocrinol Rev 2018; 16: 233– 9. 30556656
Cited by
Sorted by citations
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728 · see citing works
- Authors
- Chen, M.-B., Xu, R.-J., Zheng, Q.-H., Zheng, X.-W., & Wang, H.
- Affiliations
- Department of Emergency
- Department of Endocrinology
- Jiangsu University (CN)
- Corresponding author
- Chen, Mao-Bing
- Venue
- Medicine
- Published
- 2020-08-14
- Volume
- 99
- Issue
- 33
- Pages
- e20875
- ISSN
- 0025-7974 (ISSN-L)
- 1536-5964
- PMC
- PMC7437859
- OpenAlex
- W3049416038
- Cited by
- 17
- References
- 3
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 3 · 2023: 1 · 2022: 2 · 2021: 1 · 2020: 2
- FWCI
- 1.13
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- the Guidance Plan for Social Development of Changzhou Municipal Science and Technology (CE20175008)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- sotagliflozin, type 1 diabetes, SGLT2 inhibitors, adjuvant therapy, glycemic control, HbA1c, insulin dose reduction, weight loss, hypoglycemia, diabetic ketoacidosis, genital mycotic infections, drug safety, drug efficacy
- MeSH terms
- Diabetes Mellitus, Type 1, Glycosides, Humans, Randomized Controlled Trials as Topic, Chemotherapy, Adjuvant, Sodium-Glucose Transporter 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
